biostudies-literatureWiberg SThe Danish Heart FoundationThe Research Foundation from the Heart Centre, Copenhagen University Hospital304https://www.ebi.ac.uk/biostudies/studies/S-EPMC4929765biostudies-literatureUnknown17(1)<h4>Background</h4>Attenuating the neurological damage occurring after out-of-hospital cardiac arrest is an ongoing research effort. This dual-centre study investigates the neuroprotective effects of the glucagon-like-peptide-1 analogue Exenatide administered within 4 hours from the return of spontaneous circulation to comatose patients resuscitated from out-of-hospital cardiac arrest.<h4>Methods/design</h4>This pilot study will randomize a total of 120 unconscious patients with sustained return of spontaneous circulation after out-of-hospital cardiac arrest undergoing targeted temperature management in a blinded one-to-one fashion to a 6-hour and 15-minute infusion of either Exenatide or placebo. Patients are eligible for inclusion if resuscitated from cardiac arrest with randomization frTrialsGLP-1 analogues for neuroprotection after out-of-hospital cardiac arrest: study protocol for a randomized controlled trial.PMC492976514-R97-A5326-22819Engstrom THofsten DEHassager CKober LWiberg SThomsen JHMoller JEFrydland MSchmidt HKjaergaard JfalseGLP-1 analogues for neuroprotection after out-of-hospital cardiac arrest: study protocol for a randomized controlled trial.<h4>Background</h4>Attenuating the neurological damage occurring after out-of-hospital cardiac arrest is an ongoing research effort. This dual-centre study investigates the neuroprotective effects of the glucagon-like-peptide-1 analogue Exenatide administered within 4 hours from the return of spontaneous circulation to comatose patients resuscitated from out-of-hospital cardiac arrest.<h4>Methods/design</h4>This pilot study will randomize a total of 120 unconscious patients with sustained return of spontaneous circulation after out-of-hospital cardiac arrest undergoing targeted temperature management in a blinded one-to-one fashion to a 6-hour and 15-minute infusion of either Exenatide or placebo. Patients are eligible for inclusion if resuscitated from cardiac arrest with randomization fr2016-01-01T00:00:00Z2016 Jun2026-06-16T05:09:18.7Z2019-03-27T02:17:21ZS-EPMC49297652736348910.1186/s13063-016-1421-2